Evidence map›Paper›PMID 39739690›Full record

ArticlePloS one2024

Deciphering the interactome of Ataxin-2 and TDP-43 in iPSC-derived neurons for potential ALS targets.

Yuan Tian, Nicolette Heinsinger, Yinghui Hu, U-Ming Lim, Yi Wang, Aaron Zefrin Fernandis, Sophie Parmentier-Batteur, Becky Klein, Jason M Uslaner, Sean M Smith

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuan TianNeuroscience, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, United States of America.ORCID 0000-0001-8158-1588
Nicolette HeinsingerNeuroscience, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, United States of America.ORCID 0000-0002-7281-8800
Yinghui HuNeuroscience, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, United States of America.
U-Ming LimQuantatitive Biosciences, Merck Sharp & Dohme, Singapore, Singapore.
Yi WangNeuroscience, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, United States of America.
Aaron Zefrin FernandisQuantatitive Biosciences, Merck Sharp & Dohme, Singapore, Singapore.
Sophie Parmentier-BatteurNeuroscience, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, United States of America.
Becky KleinNeuroscience, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, United States of America.
Jason M UslanerNeuroscience, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, United States of America.
Sean M SmithNeuroscience, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ataxin-2 is a protein containing a polyQ extension and intermediate length of polyQ extensions increases the risk of Amyotrophic Lateral Sclerosis (ALS). Down-regulation of Ataxin-2 has been shown to mitigate TDP-43 proteinopathy in ALS models. To identify alternative therapeutic targets that can mitigate TDP-43 toxicity, we examined the interaction between Ataxin-2 and TDP-43. Co-immunoprecipitation demonstrated that Ataxin-2 and TDP-43 interact, that their interaction is mediated through the RNA recognition motif (RRM) of TDP-43, and knocking down Ataxin-2 or mutating the RRM domains rescued TDP-43 toxicity in an iPSC-derived neuronal model with TDP-43 overexpression. To decipher the Ataxin-2 and TDP-43 interactome, we used co-immunoprecipitation followed by mass spectrometry to identify proteins that interacted with Ataxin-2 and TDP-43 under conditions of endogenous or overexpressed TDP-43 in iPSC-derived neurons. Multiple interactome proteins were differentially regulated by TDP-43 overexpression and toxicity, including those involved in RNA regulation, cell survival, cytoskeleton reorganization, protein modification, and diseases. Interestingly, the RNA-binding protein (RBP), TAF15 which has been implicated in ALS was identified as a strong binder of Ataxin-2 in the condition of TDP-43 overexpression. Together, this study provides a comprehensive annotation of the Ataxin-2 and TDP-43 interactome and identifies potential therapeutic pathways and targets that could be modulated to alleviate Ataxin-2 and TDP-43 interaction-induced toxicity in ALS.

Indexed as

Amyotrophic Lateral SclerosisAtaxin-2DNA-Binding ProteinsInduced Pluripotent Stem CellsNeuronsHumansProtein BindingAtaxin-2ATXN2 protein, humanDNA-Binding ProteinsTARDBP protein, human

Identifiers

PMID39739690
PMCPMC11687654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.